FHLC - AbbVie - A Biotech Oscar Winning Movie

• No matter how long is the time you dedicate to look at/hold AbbVie, it's a "movie" with a happy ending, with a second-to-none acting performance.
• In spite of near-future growth concerns, and even if the stock might be (technically/optically) looking fully valued, we believe that there's still meat left on the AbbVie bone.
• Humira sales will keep slowing, but Skyrizi and Rinvoq sales are expected to fully compensate for this (and then some), bringing AbbVie back to a decent growth path.
• If you think that AbbVie has reached its fair value, let alone surpass it, you should probably unfollow the ABBV symbol and start following the TSLA symbol more closely.
• As far as we're concerned, ABBV remains a biotech Oscar nominee every year since the company was formed, even if we have to take some cautionary actions to avoid "sinning."

For further details see: